Author:
Yu Lawrence X.,Ellison Christopher D.,Conner Dale P.,Lesko Larry J.,Hussain Ajaz S.
Publisher
Springer Science and Business Media LLC
Reference16 articles.
1. Guidance for industry, Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral. Dosage Forms Based on a Biopharmaceutics Classification System August 2000, CDER/FDA. ww.fda.gov/eder/guidances/index.htm.
2. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995; 12:413–420.
3. Blume HH, Schug BS. The biopharmaceutics classification system (BCS): Class III drugs3/4better candidates for BA/BE waiver? Eur J Pharm Sci. 1999;9:117–121.
4. Yu LX, Gatlin LA, Amidon GL. Predicting gastrointestinal drug absorption in humans. In: Amidon GL, Lee PI, Topp EM, eds. Transport Processes in Pharmaceutical Systems. New York, New York, Murcel Dekker, Inc; 1999:377–409.
5. Kaus LC, Gillespie WR, Hussain AS, Amidon GL. The effect of in vivo dissolution, gastric emptying rate, and intestinal transit time on the peak exposure and total exposure on drugs with different gastrointestinal permeabilities. Pharm Res. 1999;16:272–280.
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献